EVGN · Evogene Ltd.

This Nasdaq minimum bid price notification represents a HIGH material event because it directly threatens Evogene’s continued listing on a major U.S. exchange, which impacts liquidity, institutional eligibility, and investor access. The deficiency arises exclusively from market-driven share price performance—not financial distress, governance failure, or regulatory violation—and is remediable through market action or corporate action. Nasdaq’s 180-day cure period provides operational runway, but the absence of any disclosed plan, timeline, or commitment to execute a reverse stock split means resolution remains uncertain and contingent on market conditions or future board decisions. While the filing confirms eligibility for a potential second 180-day period if certain market value and listing standards (excluding bid price) are met, that contingency requires affirmative steps—including written notice of intent to cure—none of which have been initiated. Critically, the notification has no immediate effect on trading, and Evogene’s shares continue to trade on Nasdaq Capital Market under EVGN and on the TASE under the same symbol; however, prolonged non-compliance could trigger negative sentiment, reduced analyst coverage, and increased cost of capital. The forward-looking statements in the release explicitly disclaim certainty regarding outcomes, citing macro risks including regional conflict and third-party dependency—factors that may further constrain management’s ability to influence near-term share price recovery.